Skip to main content
Alzheimer's DiseaseCognitive functionBrain and nervesDrugPhase 3

What this study is

The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease

What's being tested

  • KarXT

    Intervention · DRUG

  • KarX-EC

    Intervention · DRUG

  • Placebo

    Intervention · OTHER

All interventions

Specified dose on specified days

Study details

Official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated With Mild to Moderate Alzheimer's Disease (MINDSET 1)
Sponsor
Bristol-Myers Squibb
Conditions
Alzheimer's Disease
Enrolling
586 people
Starts
2025-07-14
Est. completion
2029-02-23
Design
Double-blind, randomized, parallel groups, Phase 3
Record
View on ClinicalTrials.gov ↗